並列タイトル等持続的腎代替療法におけるメシル酸ナファモスタットの血中動態
一般注記type:Thesis
Continuous renal replacement therapy (CRRT) is the preferred dialysis modality
in critical care settings for patients with hemodynamic instability. Nafamostat
mesylate (NM) is an anticoagulant commonly used (mainly in Japan)
during CRRT in patients with high bleeding risk. In this study, we evaluated
the pharmacokinetics of NM during CRRT. Patients undergoing CRRT
therapy and using NM as the anticoagulant in the intensive care unit were
enrolled in the study. Blood was collected from the CRRT circuit just after
blood removal, just before and after the membrane for CRRT, and from the
filtrates after the membrane. NM concentrations were measured using
high-performance liquid chromatography. NM was detected in the intracorporeal
circulation during CRRT in some cases, and liver enzymes were severely
elevated in almost all of the cases. Coagulation time was prolonged
even before the initiation of NM administration in these cases and may be
associated with liver damage. This study suggests that NM dosage should take
into account liver damage assessed by elevated liver enzymes.
博士(医学)・乙第1531号・令和5年3月15日
© 2022 by author(s) and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).
identifier:Emergency Medicine Vol.10 No.4 p.157-167 (2022 Dec)
identifier:23321806
identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/4116
identifier:Emergency Medicine, 10(4): 157-167
連携機関・データベース国立情報学研究所 : 学術機関リポジトリデータベース(IRDB)(機関リポジトリ)
提供元機関・データベース奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU